Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia
Pemphigus is a rare group of autoimmune mucocutaneous blistering conditions for which the mainstay of treatment is immunosuppression. This is usually achieved with high dose corticosteroids as well as steroid sparing agents. Rituximab is now recommended as a first line treatment for moderate to seve...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2023-03-01
|
| Seri Bilgileri: | Frontiers in Medicine |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1149742/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|